Neuralink has secured FDA approval to develop its Blindsight vision technology.
Science Corp’s vision restoration trials have been successful. 32 of 38 patients showed improvement.
These actions are supported by increased investment interest. Neuralink received 600 million US dollars and Science Corp 150 million.
The vision technology is achieved through brain-computer interfaces.
Neuralink aims to implant electrodes in the visual cortex.
Other companies such as Cellino are developing cell therapy technology.
[Source: http://www.bankingnews.gr]
